Deprenyl, a monoamine oxidase inhibitor used in the treatment of Parkinson's disease, along with its primary metabolite desmethyldeprenyl (DES) have been shown to reduce neuronal apoptosis by a mechanism that requires gene transcription and involves the maintenance of mitochondrial membrane potential. This review article explores the mechanisms by which DES maintains mitochondrial membrane potential. Mediated by GAPDH binding, DES increases mitochondrial BCL-2 and BCL-xL levels and decreases BAX levels thereby preventing the permeability transition pore (PTP) from opening and preventing apoptotic degradation. The favorable effects of deprenyl on neuronal apoptosis suggests the therapeutic potential of designing compounds with the capacity to alter the configurations of pro-apoptosis or anti-apoptotic proteins.
KerrJ.F.R.Shrinkage necrosis: a distinct form of cell death. J Pathol1971; 105: 13–20.
2.
KroemerG., ZamzamiN., SusinS.A.Mitochondrial control of apoptosis. Immunol Today1997; 18: 44–51.
3.
MazarakisN.D., EdwardsA.D., MehmetH.Apoptosis in neural development and disease. Arch Dis Child Fetal Neonatal Ed1997; 77: F165–70.
4.
LiptonS.A., NicoteraP.Calcium, free radicals and excitotoxins in neuronal apoptosis. Cell Calcium1998; 23: 165–71.
5.
TattonN.A., KishS.J.In situ detection of apoptotic nuclei in the substantia nigra compacta of 1–methyl-4-phenyl-1,2,3,6–tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neurosci1997; 77: 1037–48.
6.
GuoQ., SopherB.L., FurukawaK.Alzheimer's presenile mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals. J Neurosci1997; 17: 4212–22.
7.
WadiaJ.S., Chalmers-RedmanR.M.E., JuW.J.H., CarlileG.W., PhillipsJ.L., TattonW.G.Mitochondrial membrane potential and nuclear changes in apoptosis caused by trophic withdrawal: Time course and modification by (-)-deprenyl. J Neurosci1998; 18: 932–47.
8.
Chalmers-RedmanR.M., FraserA.D., JuW.Y., WadiaJ., TattonN.A., TattonW.G.Mechanisms of nerve cell death: apoptosis or necrosis after cerebral ischaemia. Int Rev Neurobiol1997; 40: 1–25.
9.
TattonW.G., Chalmers-RedmanR.M., JuW.Y., WadiaJ., TattonN.A.Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. J Neural Transm Suppl1997; 49: 245–68.
10.
KerriganL.A., ZackD.J., QuigleyH.A., SmithS.D., PeaseM.E.TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol1997; 115: 1031–5.
11.
OkisakaS., MurakamiA., MizukawaA., ItoJ.Apoptosis in retinal ganglion cell decrease in human glaucomatous eyes. Jpn J Ophthalmol1997; 41: 84–8.
12.
QuigleyH.A.Ganglion cell death in glaucoma: pathology recapitulates ontogeny. Aust N Z J Ophthalmol1995; 23: 85–91.
13.
QuigleyH.A., NickellsR.W., KerriganL.A., PeaseM.E., ThibauitD.J., ZackD.J.Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci1995; 36: 774–86.
14.
WaxM.B., TezelG., EdwardP.D.Clinical and ocular histopathological findings in a patient with normal-pressure glaucoma (see comments). Arch Ophthalmol1998; 116: 993–1001.
15.
SavitzS.I., RosenbaumD.M.Apoptosis in neurological disease. Neurosurg1998; 42: 555–72 (discussion 573–574).
16.
AngladeP., VyasS., HirschE.C., AgidY.Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol1997; 12: 603–10.
17.
TattonN.A., Maclean-FraserA., TattonW.G., PerlD.P., OlanowC.W.A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol1998; 44(suppl): S142–8.
18.
Group TPS.Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med1993; 328: 176–83.
19.
WardC.D.Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry1994; 57: 217–20.
20.
TattonW.G., Chalmers-RedmanR.M.Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurol Clin1996; 47: S171–83.
21.
KragtenE., LalandeI., ZimmermannK.Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem1998; 273: 5821–8.
22.
LeW., JankovicJ., XieW., KongR., AppelS.H.(-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition. Neurosci Lett1997; 224: 197–200.
23.
MaruyamaW., TakahashiT., NaoiM.(-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J Neurochem1998; 70: 2510–5.
24.
PatersonI.A., BarberA.J., GelowitzD.L., VollC.(-)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Neurosci Biobehav Rev1997; 21: 181–6.
25.
PatersonI.A., ZhangD., WarringtonR.C., BoultonA.A.R-deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium. J Neurochem1998; 70: 515–23.
TattonW.G., JuW.Y., HollandD.P., TaiC., KwanM.(-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem1994; 63: 1572–5.
28.
TattonW.G., Chalmers-RedmanR.M.Mitochondria in neurodegenerative apoptosis: an opportunity for therapy?Ann Neurol1998; 44 (suppl): S134–41.
29.
TattonW.G., OlanowC.W.Apoptosis in neurodegenerative diseases: Role of mitochondria. Biochim Biophys Acta1999 (in press).
30.
SusinS.A., ZamzamiN., KroemerG.Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta1998; 1366: 151–65.
31.
ZamzamiN., BrennerC., MarzoI., SusinS.A., KroemerG.Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene1998; 16: 2265–82.
32.
MarzoI., BrennerC., ZamzamiN.Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science1998; 281: 2027–31.
33.
IshitaniR., KimuraM., SunagaK., KatsubeN., TanakaM., ChuangD.M.An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J Pharmacol Exp Ther 1996a;278: 447–54.
34.
IshitaniR., SunagaK., HiranoA., SaundersP., KatsubeN., ChuangD.M.Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J Neurochem1996b; 66: 928–35.
35.
IshitaniR., SunagaK., TanakaM., AishitaH., ChuangD.M.Overexpression of glyceraldehyde-3-phosphate dehydrogenase is involved in low K+-induced apoptosis but not necrosis of cultured cerebellar granule cells. Mol Pharmacol1997; 51: 542–50.
36.
SunagaK., TakahashiH., ChuangD.M., IshitaniR.Glyceraldehyde-3-phosphate dehydrogenase is over-expressed during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaques from Alzheimer's brain. Neurosci Lett1995; 200: 133–6.
37.
NagyE., RigbyW.F.C.Glyceraldehyde-3-phosphate dehydrogenase selectively binds AU-rich RNA in the NAD(+)-binding region (Rossmann fold). J Biol Chem1995; 270: 2755–63.
38.
CarlileG.W., TattonW.G., BordenK.L.Demonstration of a RNA-dependent nuclear interaction between the promyelocytic leukaemia protein and glyceraldehyde-3-phosphate dehydrogenase. Biochem J1998; 335: 691–6.
39.
IshitaniR., TanakaM., SunagaK., KatsubeN., ChuangD.M.Nuclear localization of overexpressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons undergoing apoptosis. Mol Pharmacol1998; 53: 701–7.
40.
SaundersP.A., Chalecka-FranaszekE., ChuangD.M.Subcellular distribution of glyceraldehyde-3-phosphate dehydrogenase in cerebellar granule cells undergoing cytosine arabinoside-induced apoptosis. J Neurochem1997; 69: 1820–8.
ShashidharanP., Chalmers-RedmanR., YuenT.Green fluorescence protein reveals nuclear translocation of GAPDH during apoptosis in living cells. Proc Soc Neurose1998; 24: 1556.
43.
KimH., FeilI.K., VerlindeC.L., PetraP.H., HolW.G.Crystal structure of glycosomal glyceraldehyde-3-phosphate dehydrogenase from Leishmania mexicana: implications for structure-based drug design and a new position for the inorganic phosphate binding site. J Biochem1995; 34: 14975–86.
44.
WrightD.A., SicilianoM.J., BaptistJ.N.Genetic evidence for the tetramer structure of glyceraldehyde-3-phosphate dehydrogenase. Experientia1972; 28: 888–9.
45.
ItogaM., TsuchiyaM., IshinoH., ShimoyamaM.Nitric oxide-induced modification of glyceraldehyde-3-phosphate dehydrogenase with NAD(+) is not ADP-ribosylation. J Biochem1997; 121: 1041–6.
46.
BeckmanJ.S., KoppenolW.H.Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and the ugly. Am J Physiol: Cell Physiol1996; 40: C1424–37.
McDonaldL.J., MossJ.Nitric oxide and NAD-dependent protein modification. Mol Cell Biochem1994; 138: 201–6.
49.
ZhangJ., SnyderS.H.Nitric oxide in the nervous system. Ann Rev Pharmacol Toxicol1995; 35: 213–33.
50.
MorgeneggG., WinklerG.C., HubscherU., HeizmannC.W., MousJ., KuenzleC.C.Glyceraldehyde-3-phosphate dehydrogenase is a nonhistone protein and a possible activator of transcription in neurons. J Neurochem1986; 47: 54–62.
51.
MintonA.P., WilfJ.Effect of macromolecular crowding upon the structure and function of an enzyme: glyceraldehyde-3-phosphate dehydrogenase. J Biochem1981; 20: 4821–6.
52.
BuysY.M., TropeG.E., TattonW.G.(-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush. Curr Eye Res1995; 14: 119–26.
